EKF Diagnostics Holdings PLC
LSE:EKF

Watchlist Manager
EKF Diagnostics Holdings PLC Logo
EKF Diagnostics Holdings PLC
LSE:EKF
Watchlist
Price: 27 GBX 0.37% Market Closed
Market Cap: 122.5m GBX
Have any thoughts about
EKF Diagnostics Holdings PLC?
Write Note

EKF Diagnostics Holdings PLC
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

EKF Diagnostics Holdings PLC
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
EKF Diagnostics Holdings PLC
LSE:EKF
Operating Income
ÂŁ6.8m
CAGR 3-Years
-31%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Smith & Nephew PLC
LSE:SN
Operating Income
$696m
CAGR 3-Years
-2%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
LivaNova PLC
NASDAQ:LIVN
Operating Income
$133.4m
CAGR 3-Years
N/A
CAGR 5-Years
11%
CAGR 10-Years
4%
Angle PLC
LSE:AGL
Operating Income
-ÂŁ19.4m
CAGR 3-Years
-5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Creo Medical Group PLC
LSE:CREO
Operating Income
-ÂŁ25.1m
CAGR 3-Years
-2%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
B
Belluscura PLC
LSE:BELL
Operating Income
-$11.1m
CAGR 3-Years
-79%
CAGR 5-Years
-50%
CAGR 10-Years
N/A
No Stocks Found

EKF Diagnostics Holdings PLC
Glance View

Market Cap
122.5m GBX
Industry
Health Care

EKF Diagnostics Holdings Plc is a vitro diagnostics company, which designs and manufactures diagnostic equipment for use within point-of-care settings. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2002-06-05. The firm's point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases. Its Central Laboratory division includes a range of products for use in both large and small laboratory facilities. Its subsidiary, EKF Life Sciences, provides bulk diagnostic enzyme manufacturing and fermentation services. EKF Life Sciences specializes in producing enzymes, including Salicylate Hydroxylase and Beta-Hydroxybutyrate Dehydrogenase. Its products include Quo-Test A1c, Biosen, Quo-Lab A1c, UltraCrit, DiaSpect, HemataStat II and Creamatocrit Plus. The company operates in Germany, the United States, Russia and the United Kingdom.

EKF Intrinsic Value
32.15 GBX
Undervaluation 16%
Intrinsic Value
Price

See Also

What is EKF Diagnostics Holdings PLC's Operating Income?
Operating Income
6.8m GBP

Based on the financial report for Jun 30, 2024, EKF Diagnostics Holdings PLC's Operating Income amounts to 6.8m GBP.

What is EKF Diagnostics Holdings PLC's Operating Income growth rate?
Operating Income CAGR 5Y
1%

Over the last year, the Operating Income growth was 76%. The average annual Operating Income growth rates for EKF Diagnostics Holdings PLC have been -31% over the past three years , 1% over the past five years .

Back to Top